A carregar...
Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
A majority of patients with a V600x melanoma respond quickly to BRAF/MEK inhibition (BRAFi/MEKi) and have an obvious clinical benefit. Nearly all the patients after this initial phase will develop resistance. Therefore, non-invasive early markers of response/non-response are needed in order to ident...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5908289/ https://ncbi.nlm.nih.gov/pubmed/29682188 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24709 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|